Vaxxinity, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink

29 Apr 2024

VAXX

10-K/A: Vaxxinity Files Amended 10-K to Include Omitted Information and Update Exhibits

Vaxxinity has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters, as well as updated exhibits.

OTC.Pink

27 Mar 2024

VAXX

Vaxxinity, INC

10-K: Vaxxinity's 10-K Filing: Focus on Chronic Disease Immunotherapies and COVID-19 Booster

Vaxxinity's 10-K filing highlights its progress in developing active immunotherapies for chronic diseases and a COVID-19 booster, while also acknowledging financial uncertainties and reliance on related parties.